Pharmacologic management of dental anxiety: Conscious versus unconscious sedation

Journal of Clinical Psychopharmacology

Volumn 26, Issue 1, 2006, Pages 1-3

  Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; MIDAZOLAM; TRIAZOLAM;

ANXIETY DISORDER; BLOOD BRAIN BARRIER; CONSCIOUSNESS; DENTAL ANXIETY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFECT; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; EDITORIAL; EGO DEVELOPMENT; FIRST PASS EFFECT; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SEDATION; TABLET;

ANESTHESIA, DENTAL; ANTI-ANXIETY AGENTS; CONSCIOUS SEDATION; DENTAL ANXIETY; DRUG ADMINISTRATION SCHEDULE; HUMANS; TRIAZOLAM;

EID: 31544453306     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000200150.79850.8d     Document Type: Editorial

References (35)

1. Dionne RA, Gordon SM, McCullagh LM, et al. Assessing the need for anesthesia and sedation in the general population. J Am Dent Assoc. 1998;129:167-173.
2. McGoldrick P, Levitt J, de Jongh A, et al. Referrals to a secondary care dental clinic for anxious adult patients: implications for treatment. Br Dent J. 2001;191:686-688.
3. Jackson DL, Johnson BS. Inhalational and enteral conscious sedation for the adult dental patient. Dent Clin North Am. 2002;46:781-802.
4. Morgan CL, Skelly AM. Conscious sedation services provided in secondary care for restorative dentistry in the UK: a survey. Br Dent J. 2005;198:631-635; discussion, p 625.
5. Wolf DL, Desjardins PJ, Black PM, et al. Anticipatory anxiety in moderately to highly-anxious oral surgery patients as a screening model for anxiolytics: evaluation of alprazolam. J Clin Psychopharmacol. 2003;23:51-57.
6. Erlandsson AL, Backman B, Stenstrom A, et al. Conscious sedation by oral administration of midazolam in paediatric dental treatment. Swed Dent J. 2001;25:97-104.
7. Berthold CW, Dionne RA, Corey SE. Comparison of sublingually and orally administered triazolam for premedication before oral surgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84:119-124.
8. Berthold CW, Schneider A, Dionne RA. Using triazolam to reduce dental anxiety. J Am Dent Assoc. 1993;124:58-64.
9. Raadal M, Coldwell SE, Kaakko T, et al. A randomized clinical trial of triazolam in 3- to 5-year-olds. J Dent Res. 1999;78:1197-1203.
10. Tweedy CM, Milgrom P, Kharasch ED, et al. Pharmacokinetics and clinical effects of sublingual triazolam in pediatric dental patients. J Clin Psychopharmacol. 2001;21:268-272.
11. Scavone JM, Greenblatt DJ, Friedman H, et al. Enhanced bioavailability of triazolam following sublingual versus oral administration. J Clin Pharmacol. 1986;26:208-210.
12. Jackson DL, Kharasch ED, Heacox GA, et al. Pharmacokinetics and clinical effects of multi-dose sublingual triazolam in healthy volunteers. J Clin Psychopharmacol. 2006;26:4-8.
13. Friedman H, Greenblatt DJ, Burstein ES, et al. Population study of triazolam pharmacokinetics. Br J Clin Pharmacol. 1986;22:639-642.
14. Greenblatt DJ, Harmatz JS, Engelhardt N, et al. Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics: flurazepam, temazepam, and triazolam. Arch Gen Psychiatry. 1989;46:326-332.
15. Ochs HR, Greenblatt DJ, Arendt RM, et al. Pharmacokinetic non-interaction of triazolam and ethanol. J Clin Psychopharmacol. 1984;4:106-107.
16. Greenblatt DJ, Divoll M, Abernethy DR, et al. Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity. Br J Clin Pharmacol. 1983;15:303-309.
17. Greenblatt DJ, Harmatz JS, Shapiro L, et al. Sensitivity to triazolam in the elderly. N Engl J Med. 1991;324:1691-1698.
18. Greenblatt DJ, Shader RI, Divoll M, et al. Adverse reactions to triazolam, flurazepam, and placebo in controlled clinical trials. J Clin Psychiatry. 1984;45:192-195.
19. Schou JS. Triazolam: adverse effects in relation to dosage. Pharmacol Toxicol. 1989;64:6-8.
20. Evans SM, Funderburk FR, Griffiths RR. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther. 1990;255:1246-1254.
21. Rush CR, Madakasira S, Hayes CH, et al. Trazodone and triazolam: acute subject-rated and performance-impairing effects in healthy volunteers. Psychopharmacology. 1997;131:9-18.
22. Deberdt R. Long-term use of triazolam, a benzodiazepine hypnotic. Curr Ther Res. 1979;26:1005-1014.
23. Roth T, Roehrs TA, Zorick FJ. Pharmacology and hypnotic efficacy of triazolam. Pharmacotherapy. 1983;3:137-148.
24. Pakes GE, Brogden RN, Heel RC, et al. Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia. Drugs. 1981;22:81-110.
25. Gupta SK, Ellinwood EH, Nikaido AM, et al. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. I: Lorazepam. J Pharmacokinet Biopharm. 1990;18:89-102.
26. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J Pharmacol Exp Ther. 2000;293:435-443.
27. Greenblatt DJ, Harmatz JS, Gouthro TA, et al. Distinguishing a benzodiazepine agonist (triazolam) from a non-agonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin Pharmacol Ther. 1994;56:100-111.
28. Laurijssens BE, Greenblatt DJ. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet. 1996;30:52-76.
29. Greenblatt DJ, von Moltke LL, Ehrenberg BL, et al. Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. Crit Care Med. 2000;28:2750-2757.
30. Venkatakrishnan K, Culm KE, Ehrenberg BL, et al. Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. J Clin Pharmacol. 2005;45:529-537.
31. Stanski DR. Pharmacodynamic modeling of anesthetic EEG drug effects. Annu Rev Pharmacol Toxicol. 1992;32:423-447.
32. Colburn WA. Simultaneous pharmacokinetic and pharmacodynamic modeling. J Pharmacokinet Biopharm. 1981;9:367-388.
33. Dingemanse J, Danhof M, Breimer DD. Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview. Pharmacol Ther. 1988;38:1-52.
34. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981;6:429-453.
35. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to D-tubocurarine. Clin Pharmacol Ther. 1979;25:358-371.